22.08.2018
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Biological Wound Care - BRAIN AG announces the creation of SolasCure Ltd. to continue development of Aurase(R)
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Strategic Company Decision
B.R.A.I.N. Biotechnology Research And Information Network AG: Biological
Wound Care - BRAIN AG announces the creation of SolasCure Ltd. to continue
development of Aurase(R)
22.08.2018 / 08:34
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biological Wound Care
BRAIN AG announces the creation of SolasCure Ltd. to continue development of
Aurase(R)
* Successful close of SolasCure's Series A financing round with
participation from BRAIN
* SolasCure brings expertise in the development and approval of medical
devices; Prof. Keith Harding (CBE) acting as Chairman of the Medical
Advisory Board
* BRAIN is providing IP and fully integrating their development programme
for biological wound care based on the Aurase(R) enzyme into SolasCure
Zwingenberg, Germany
Cardiff, United Kingdom
August 22, 2018
BRAIN AG, a German listed industrial biotechnology company, announces its
participation in the creation of SolasCure Ltd. based in Cardiff, Wales, UK.
SolasCure will be responsible for the development, CE certification and
marketing of medical products based on Aurase(R), a new enzymatic active
ingredient developed by BRAIN for the biological cleaning of chronic wounds.
Investors including BRAIN participated in SolasCure's successful Series A
financing round. BRAIN has licensed IP for the commercialization of future
Aurase(R)-based products and will supply the novel enzymatic ingredient.
SolasCure has been co-founded by Dr Sam Bakri, a serial healthcare
entrepreneur who has been appointed as Executive Chairman. Professor Keith
Harding (CBE), founder of the Welsh Wound Innovation Centre and expert in
wound bed preparation has been appointed Chairman of the Medical Advisory
Board.
Commenting on SolasCure's potential, Co-founder and Executive Chairman Sam
Bakri said: "Aurase(R) is an extraordinary innovation with great potential
impact for healthcare. SolasCure is focused on the continued development of
Aurase(R) so we can offer the many patients suffering from chronic wounds a
treatment. We have brought together a team experienced in the development of
medical devices for wound healing, under the professional guidance of
Professor Keith Harding".
The spin-off of the Aurase(R) development programme into SolasCure Ltd. is
part of BRAIN's strategy to strengthen its business growth. Following the
founding of U.S. based BRAIN LLC. in February 2018, the acquisition of a
majority stake of UK based Biocatalysts Ltd. in March 2018 and the
announcement of the strategic partnership with the German Evonik subsidiary
CyPlus GmbH of June 2018, this is another step to strengthen the industrial
business of BRAIN Group.
Frank Goebel, CFO of BRAIN AG and member of the Board of Directors of
SolasCure emphasizes: "With BRAIN's technological know-how, Aurase(R)
development has already made significant progress. In order to accelerate
the development and bring together the relevant regulatory and market
expertise, we decided to spin off the business into a separate company,
supported by additional investors and expertise. The SolasCure team is
confident that it will be able to achieve first product launches of
Aurase(R)-containing
medical devices as early as 2021, thus accelerating the business development
of BRAIN AG."
Aurase(R) is protected by an extensive patent estate (WO 2010/099955). The
basis of Aurase(R) is a protein-degrading enzyme developed from natural
resources. Researchers at BRAIN identified that the maggot of the green
bottle fly (also called "gold-fly") secretes an enzyme that dissolves
necrotic tissue. This protease has been isolated and cloned from medical
maggots enabling it to be produced in a GMP biotechnological process under
the direction of BRAIN AG. This product will be supplied to SolasCure for
further integration into medical devices.
The medical use of Aurase(R) should lead to faster wound cleaning -
promoting better patient outcomes and reducing healthcare costs. According
to Global Industry Analysts Inc., approximately 40.5 million patients
worldwide suffered from chronic wounds in 2015, including cases of diabetic
foot, pressure sores and other chronic wounds such as Ulcus curis.
Physicians expect this number to increase in the coming years due to an
increase in type 2 diabetes and an aging patient population. According to a
2017 study by Markets and Markets, the global wound treatment market is
estimated at USD 22 billion. The annual growth rate is estimated at 3.7%
between 2017 and 2022.
BRAIN
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.de
Contact Investor Relations
Dr. Martin Langer
Executive Vice President
Corporate Development
Tel.: +49-6251-9331-16
E-Mail: [email protected]
Contact Media
Thomas Deichmann
Head of Public Relations
Tel.: +49-6251-9331-72
E-Mail: [email protected]
SolasCure Ltd.
Cefn Coed Unit 1, Cefn Coed, Nantgarw, Cardiff,
Wales, CF15 7QQ
United Kingdom
Tel.: +44-2921690111
E-Mail: [email protected]
www.solascure.com
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN
DE0005203947 / WKN 520394) is one of Europe's leading technology companies
in the field of industrial biotechnology, the core discipline of Bioeconomy.
As such, BRAIN identifies previously untapped, efficient enzymes, microbial
producer organisms or natural substances from complex biological systems
that can be put to industrial use. The innovative solutions and products
developed by help of this "Toolbox of Nature" are successfully applied in
the chemistry, the cosmetics and the food industries. BRAIN's business model
is based on two pillars - BioScience and BioIndustrial. The BioScience
segment comprises its frequently exclusive collaboration business with
industrial partners. BioIndustrial comprises the development and
commercialization of BRAIN's own products and active product components.
Further information is available at www.brain-biotech.de/en.
About SolasCure
SolasCure Limited (Company Nº 10826246) aims to support healthcare
professionals with wound care products that significantly improve the health
and wellbeing of patients with chronic wounds. Chronic wounds impact over 40
million people worldwide, with care consuming around 10% of health care
expenditure in many countries; while spending on advanced wound care
products is over £5 billion each year. These figures continue to grow as
prevalence of obesity and diabetes increases. SolasCure's first product,
Aurase(R) is a hydrogel containing a safe, active, highly-specific enzyme,
isolated and cloned from medical maggots. The medical use of Aurase(R)
should lead to faster wound cleaning - promoting better patient outcomes and
reduced healthcare costs. Further information is available at
www.solascure.com.
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. There are numerous factors which
could influence the future performance by and future developments at BRAIN
AG and the BRAIN group of companies. Such factors include, but are not
limited to, changes in the general economic and competitive environment,
risks associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, and other factors. BRAIN AG does
not undertake any obligation to update or revise any forward-looking
statements.
---------------------------------------------------------------------------
22.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
716091 22.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN